Trial ID or NCT#
NCT01912534
Status
NOT RECRUITING
Purpose
The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.
Official Title
Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM
Eligibility Criteria
Ages Eligible for Study: 8 Years to 45 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Investigator(s)
Euan A. Ashley
Cardiologist
Associate Dean, School of Medicine, Professor of Medicine (Cardiovascular), of Genetics, of Biomedical Data Science and, by courtesy, of Pathology at the Stanford University Medical Center
Matthew Wheeler
Cardiologist
Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Contact us to find out if this trial is right for you.
CONTACT
Euan Ashley, MD, PhD
(650) 498-4900
View on ClinicalTrials.gov